首页> 外文期刊>International journal of infectious diseases : >The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups
【24h】

The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups

机译:曲霉病的经济影响:跨患者亚组的医院支出分析

获取原文
           

摘要

SummaryObjective To measure the impact of invasive aspergillosis infection on US hospital costs and financial performance across different patient populations.Methods Hospital discharge data for patients with a primary or secondary diagnosis of aspergillosis were extracted from the 2003 Nationwide Inpatient Sample (NIS) and the fiscal year 2003 (FYO3) Medicare Provider Analysis and Review (MedPAR) file. The data on patient demographics, length of stay (LOS), hospital charges, estimated costs, and reimbursement levels were reported. After controlling for comorbidities, operative procedures, and diagnosis-related group (DRG) assignment, the clinical and economic outcomes were compared for patients with and without aspergillosis.Results The NIS contains a total of over 38 million projected hospital discharges. From these, 10?400 aspergillosis cases were identified across 171 DRGs, resulting in a US incidence rate of 36 per million per year. The mean age of aspergillosis patients was 55.6 years, with 53.4% male and 67.9% Caucasian. The median (mean) LOS per aspergillosis patient was 10 (17.7) days, with a median (mean) total hospital charge (THC) of $44?845 ($96?731). Among the patient subgroups analyzed, the median (mean) THC per patient ranged from $47?252 ($82?946) for HIV to $413?200 ($442?233) for bone marrow transplant (BMT). When compared to the non-aspergillosis patient population, the data showed a significant increase in LOS, THC, and hospital costs. Furthermore, the higher hospital costs associated with aspergillosis patients were not matched by similar increases in reimbursements, resulting in a greater financial loss for hospitals. The mean reimbursement-to-cost ratio for aspergillosis cases across the DRGs analyzed was 0.80.Conclusions Aspergillosis affects a wide range of patient groups and has a negative economic impact across many DRGs. Improved prevention, diagnosis, and patient management strategies can help mitigate these effects on hospital financial performance.
机译:摘要目的目的测量侵袭性曲霉菌感染对不同患者人群的美国医院成本和财务绩效的影响。方法从2003年全国住院患者样本(NIS)和会计年度中提取具有曲霉菌病主要或次要诊断的患者的出院数据2003(FYO3)医疗保险提供者分析和审查(MedPAR)文件。报告了有关患者人口统计数据,住院时间(LOS),医院收费,估计费用和报销水平的数据。在控制了合并症,手术程序和诊断相关组(DRG)的分配后,比较了有和没有曲霉菌病的患者的临床和经济结果。结果NIS总共计划出院3,800万例。从这些中,在171个DRG中鉴定出10-400例曲霉菌病病例,导致美国每年的发病率为36 /百万。曲霉病患者的平均年龄为55.6岁,其中男性为53.4%,白种人为67.9%。每名曲霉病患者的平均(LOS)住院天数为10(17.7)天,平均总住院费用(THC)为$ 44-845($ 96-731)。在所分析的患者亚组中,每位患者的THC中位数(范围)从HIV的47-252美元(82-946美元)到骨髓移植(BMT)的413-200美元(442-233美元)不等。与非曲霉病患者人群相比,数据显示LOS,THC和医院费用显着增加。此外,与曲霉菌病患者相关的更高的医院费用并没有得到类似的报销增加,这导致了医院更大的经济损失。所分析的整个DRG中曲霉病病例的平均报销成本比为0.80。结论曲霉病影响广泛的患者群体,并对许多DRG产生负面的经济影响。改进的预防,诊断和患者管理策略可以帮助减轻这些对医院财务绩效的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号